Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 649

1.

Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.

Novaes HM, de Soárez PC, Silva GA, Ayres A, Itria A, Rama CH, Sartori AM, Clark AD, Resch S.

Vaccine. 2015 May 7;33 Suppl 1:A135-42. doi: 10.1016/j.vaccine.2014.12.031.

PMID:
25919154
2.

Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.

Aguilar IB, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, Perdomo G, Garcia AG, Janusz CB.

Vaccine. 2015 May 7;33 Suppl 1:A167-73. doi: 10.1016/j.vaccine.2014.12.067.

PMID:
25919157
3.

Cost-effectiveness of HPV vaccination in Belize.

Walwyn L, Janusz CB, Clark AD, Prieto E, Waight E, Largaespada N.

Vaccine. 2015 May 7;33 Suppl 1:A174-81. doi: 10.1016/j.vaccine.2014.12.042.

PMID:
25919158
4.

Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).

Kim JJ, Sharma M, O'Shea M, Sweet S, Diaz M, Sancho-Garnier H, Seoud M.

Vaccine. 2013 Dec 30;31 Suppl 6:G65-77. doi: 10.1016/j.vaccine.2012.06.096.

PMID:
24331822
5.

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.

Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.

Vaccine. 2008 Jul 29;26(32):4080-93. doi: 10.1016/j.vaccine.2008.04.053. Epub 2008 May 15.

PMID:
18550229
7.

Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model.

Kawai K, de Araujo GT, Fonseca M, Pillsbury M, Singhal PK.

BMC Infect Dis. 2012 Oct 9;12:250. doi: 10.1186/1471-2334-12-250.

8.

Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.

Gomez JA, Lepetic A, Demarteau N.

BMC Public Health. 2014 Nov 26;14:1222. doi: 10.1186/1471-2458-14-1222.

9.

A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.

Hutubessy R, Levin A, Wang S, Morgan W, Ally M, John T, Broutet N.

BMC Med. 2012 Nov 13;10:136. doi: 10.1186/1741-7015-10-136.

10.

Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.

Võrno T, Lutsar K, Uusküla A, Padrik L, Raud T, Reile R, Nahkur O, Kiivet RA.

Vaccine. 2017 Nov 1;35(46):6329-6335. doi: 10.1016/j.vaccine.2017.08.083. Epub 2017 Sep 9.

PMID:
28899625
11.

A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy.

Favato G, Baio G, Capone A, Marcellusi A, Saverio Mennini F.

Clin Ther. 2013 Jul;35(7):904-14. doi: 10.1016/j.clinthera.2013.05.003. Epub 2013 Jun 24.

PMID:
23806328
12.

Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.

Demarteau N, Van Kriekinge G, Simon P.

Vaccine. 2013 Aug 20;31(37):3962-71. doi: 10.1016/j.vaccine.2013.06.008. Epub 2013 Jun 15.

13.

Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.

Kim JJ, Campos NG, O'Shea M, Diaz M, Mutyaba I.

Vaccine. 2013 Dec 29;31 Suppl 5:F60-72. doi: 10.1016/j.vaccine.2012.07.093.

PMID:
24331749
14.

Cost-Effectiveness Analysis of the Introduction of HPV Vaccination of 9-Year-Old-Girls in Iran.

Yaghoubi M, Nojomi M, Vaezi A, Erfani V, Mahmoudi S, Ezoji K, Zahraei SM, Chaudhri I, Moradi-Lakeh M.

Value Health Reg Issues. 2018 May;15:112-119. doi: 10.1016/j.vhri.2018.03.001. Epub 2018 Apr 24.

PMID:
29698864
15.

Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.

Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim JJ.

Vaccine. 2013 Dec 31;31 Suppl 7:H71-9. doi: 10.1016/j.vaccine.2013.04.086.

PMID:
24332299
16.

Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.

Brisson M, Laprise JF, Chesson HW, Drolet M, Malagón T, Boily MC, Markowitz LE.

J Natl Cancer Inst. 2015 Oct 4;108(1). pii: djv282. doi: 10.1093/jnci/djv282. Print 2016 Jan.

PMID:
26438574
17.

Mathematical models of cervical cancer prevention in the Asia Pacific region.

Goldie SJ, Diaz M, Kim SY, Levin CE, Van Minh H, Kim JJ.

Vaccine. 2008 Aug 19;26 Suppl 12:M17-29. doi: 10.1016/j.vaccine.2008.06.018.

PMID:
18945411
18.

Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary.

Vokó Z, Nagyjánosi L, Kaló Z.

BMC Public Health. 2012 Oct 30;12:924. doi: 10.1186/1471-2458-12-924.

19.

An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.

Levin CE, Sharma M, Olson Z, Verguet S, Shi JF, Wang SM, Qiao YL, Jamison DT, Kim JJ.

Vaccine. 2015 Jun 4;33(24):2830-41. doi: 10.1016/j.vaccine.2015.02.052. Epub 2015 Mar 12.

20.

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G.

Sex Health. 2007 Sep;4(3):165-75.

PMID:
17931529

Supplemental Content

Support Center